Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × GIST × Sarcoma × Clear all

Phase

Status

Completed 4 Unknown 2 Recruiting 1 Not yet recruiting 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 241 Osteosarcoma 67 Sarcoma, Ewing 50 Melanoma 42 Neoplasms 37 Colorectal Neoplasms 36 Breast Neoplasms 36 Gastrointestinal Stromal Tumors 35 Rhabdomyosarcoma 33 Bone Neoplasms 33 Stomach Neoplasms 30 Pancreatic Neoplasms 29 Ovarian Neoplasms 29 Neoplasm Metastasis 29 Neuroblastoma 25 Lung Neoplasms 24 Dendritic Cell Sarcoma, Interdigitating 24 Uterine Cervical Neoplasms 22 Esophageal Neoplasms 22 Leiomyosarcoma 21 Carcinoma, Non-Small-Cell Lung 21 Liposarcoma 20 Head and Neck Neoplasms 20 Urinary Bladder Neoplasms 19 Lymphoma 18 Endometrial Neoplasms 18 Sarcoma, Kaposi 17 Glioblastoma 17 Carcinoma, Hepatocellular 17 Sarcoma, Synovial 16

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡